The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Addressing unmet needs in multiple myeloma: a preview of the MYELOMAS meeting
Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, discusses what to expect at the upcoming MYELOMAS meeting in Rome, Italy. Dr Cerchione highlights that the meeting will cover key topics in the diagnosis and treatment of multiple myeloma, including the sequencing of new drugs and combinations, sustained measurable residual disease (MRD) negativity as an emerging endpoint, and the treatment of high-risk smoldering myeloma, including the need for improved diagnostic tools. This interview took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
